Severe aortic stenosis causes pressure overload of the left ventricle, resulting in progressive cardiac dysfunction that can extend beyond the left ventricle. A staging system for aortic stenosis has been recently proposed that quantifies the extent of structural and functional cardiac changes in aortic stenosis.
T he pathophysiologic process of aortic stenosis has both valvular and extravalvular involvement. With aortic stenosis progression, the pressure overload leads to compensatory left ventricular hypertrophy; diastolic dysfunction; an increase in left atrial size; the development of mitral and tricuspid regurgitation; and an increase in pulmonary artery pressures. In later stages, biventricular dysfunction tends to occur, which represents a far advanced process. [1] [2] [3] [4] The updated 2014 American College of Cardiology/American Heart Association guidelines for management of valvular heart disease recommended aortic valve replacement in the setting of severe aortic stenosis and symptoms (which are often multifactorial in the older population) or in the event of left ventricular ejection fraction decline (which can be at times late and irreversible).
5
Transcatheter aortic valve replacement (TAVR) has become the main method of aortic valve intervention that delivers excellent results in patients with intermediate to high surgical risk. [6] [7] [8] [9] [10] [11] Given that many risk factors could account for and/or contribute to the observed differences in post-TAVR outcomes, evaluation and integration of valvular-related cardiac dysfunctions, beyond those included in the traditional risk scores and predictive models, become extremely relevant. 12 A recent study by Généreux et al, 13 using data from the PARTNER (Placement of Aortic Transcatheter Valves) randomized clinical trial, proposed the first integrated staging system to quantify the extent of cardiac changes associated with aortic stenosis and the association of those changes with 1-year mortality in patients who underwent either surgical aortic valve replacement or TAVR. Using a large and homogeneous cohort of patients with severe aortic stenosis who received TAVR at our integrated health care system, we sought to (1) confirm the reproducibility of the proposed staging system and expand the study findings by performing a survival analysis for up to 2 years after TAVR and (2) evaluate the association of aortic stenosis staging with both cardiac and noncardiac post-TAVR readmissions.
Methods

Study Design
We conducted a retrospective cohort analysis of patients who underwent TAVR at the University of Pittsburgh Medical Center (Pittsburgh, Pennsylvania), a large, integrated health care system, between July 1, 2011, and January 31, 2017. This study was approved by the institutional review board of the University of Pittsburgh. Informed consent was waived because of the retrospective nature of this study and analysis. We excluded patients who had undergone TAVR for valvein-valve procedures, as the fundamental association between cardiac structure or function and clinical outcomes may be different for patients with previous aortic valve intervention. We also excluded patients with incomplete or unavailable baseline echocardiogram study for review to allow for adequate staging classification. Patients underwent comprehensive clinical evaluation by the designated heart team and were deemed appropriate to undergo TAVR as suggested by the guidelines. Clinical, laboratorial, and procedural data were collected from the Society of Thoracic Surgeons (STS)/American College of Cardiology Transcatheter Valve Therapy Registry database at the health care system and augmented by review of electronic medical records.
Outcomes
The primary outcome was all-cause mortality and was obtained through querying the electronic medical records and the updated Social Security Administration Death Master file, for which the health care system is exempt from the 3-year delay period by the Social Security Administration. The secondary outcomes were composite outcomes of all-cause death and post-TAVR all-cause or cardiac-cause readmission.
All-cause readmission was defined as any admission irrespective of the underlying cause. Cardiac-cause readmission was defined as admission associated with any of the top 5 primary diagnoses established by the International Classification 
Study Procedures
All patients included in this study who underwent TAVR evaluation received comprehensive transthoracic echocardiography using commercial systems (iE33 and CX50 models [Philips Medical Systems]; Vivid 7/E9/E95 ECG Stress Cable Kit [General Electric]). All individual echocardiographic images and Doppler data were independently reviewed according to guidelines and their clinical information and outcomes masked. For all Doppler quantification, 3 consecutive heart cycles were recorded and the mean calculated for patients in sinus rhythm, whereas the mean of 5 cardiac cycles was calculated for those in atrial fibrillation.
Using the same staging classification system proposed by Généreux et al, 13 we classified patients into the following stages: 
Statistical Analysis
Categorical variables are presented as frequency (percentage) and were compared using the χ 2 test. In the case of selected variables in which a single cell had fewer than 5 patients, Fisher exact test was used. Continuous variables are presented as mean (SD) and were compared using unpaired, 1-way analysis of variance. A 2-sided P < .05 was considered statistically significant. Two-year survival rates and a composite outcome of allcause death and readmission rates after TAVR within each group are displayed using Kaplan-Meier curves. Cox proportional hazards regression models were used to estimate the difference in 2-year survival and post-TAVR readmission rates between the aortic stenosis stages when adjusting for surgical risk and burden of comorbidities using the STS Predicted Risk of Mortality (PROM) scoring system (score range: 5.0%-10.4%, with the highest score indicating increased 30-day mortality risk for aortic valve replacement; a score between 4% and 8% was considered intermediate risk, whereas >8% defined high-risk). All statistical analyses were performed using SAS, version 9.4 (SAS Institute Inc).
Results
Study Population
During the study period (July All-cause post-transcatheter aortic valve replacement (TAVR) mortality (A) and composite outcomes of all-cause deaths and readmissions (B) or cardiac-cause readmissions (C) increased with each stage of worsening cardiac dysfunction. Log-rank χ 2 forAwas24.98(P < .001); for B, 12.77 (P = .005); and for C, 12.59 (P = .006). 
Research Original Investigation
Outcomes
During a median (interquartile range) follow-up of 20.1 (10-32) months after TAVR, 203 all-cause deaths (cumulative event rate, 29.5%), 277 all-cause readmissions (40.2%), 240 cardiaccause readmissions (34.8%), 372 composite outcomes of all-cause deaths and all-cause readmissions (54.0%), and 355 composite outcomes of all-cause deaths and cardiac-cause readmissions (51.5%) occurred. The absolute number of events and cumulative event rate in each of the groups are shown in eTable 2 in the Supplement.
The aortic stenosis staging system showed a strong graded association between the extent of cardiac changes and post-TAVR all-cause mortality ( Figure 1A ). The differences between groups remained statistically significant after adjusting for STS-PROM score (Table 3 and Figure 2A ). Patients presenting with stage 4 aortic stenosis had the highest risk of undergoing TAVR (hazard ratio [HR] vs stage 1, 2.83; 95% CI, 1.39-5.76; P = .004), followed by patients with stage 3 (HR vs stage 1, 2.24; 95% CI, 1.28-3.92; P = .005); patients with stage 2 aortic stenosis did not have statistically significantly greater risk compared with stage 1 (HR, 1.37; 95% CI, 0.81-2.31; P = .25).
Despite adjustment for STS-PROM score, patients with stage 3 also had the highest post-TAVR rates for both all-cause (HR vs stage 1, 1.64; 95% CI, 1.06-2.54; P = .03) and cardiac-cause (HR vs stage 1, 1.84; 95% CI, 1.13-3.00; P = .01) readmissions (Table 3) .
Unadjusted ( Figure 1 ) and adjusted survival analysis using baseline STS-PROM score (Figure 2) showed a statistically significant graded association between the extent of cardiac changes in the staging system and composite all-cause deaths and all-cause readmissions as well as all-cause deaths and cardiac-cause readmissions. Of importance, patients with stage 3 who have substantial pulmonary hypertension and/or tricuspid regurgitation had not only higher mortality risk but also higher readmission rates for both cardiac and noncardiac causes.
Discussion
In the current study, we evaluated the association of aortic stenosis staging with both cardiac and noncardiac post-TAVR readmissions as well as the 2-year post-TAVR all-cause mortality in a large selected population. Our findings confirm and support the findings by Généreux et al, 13 demonstrating that the extent of cardiac changes in the proposed aortic stenosis staging system has a graded association with all-cause mortality during a long-term, 2-year, post-TAVR follow-up of patients. In addition, to our knowledge, we report for the first time that the proposed staging classification system is also associated with post-TAVR readmissions for both cardiac and noncardiac causes, particularly for patients with advanced pulmonary hypertension and moderate to severe tricuspid regurgitation. This association is maintained after adjustment for other traditional risk factors and comorbid conditions through the use of the comprehensive STS-PROM scoring system, making a compelling case for the inclusion of this staging system in future TAVR risk stratification models and shared decision making.
TAVR Risk Stratification
Randomized clinical trials have established the safety and efficacy of TAVR in the treatment of symptomatic severe aortic stenosis. [8] [9] [10] [11] Advances in valve technology, operative techniques, and post-TAVR care have contributed to remarkable improvements in TAVR results and its wide adoption, but patient selection and risk stratification remain the cornerstone and areas of continued learning in TAVR. Increased knowledge and refinements of patient selection have led to the recognition of important comorbidities, which could also affect TAVR outcomes. [14] [15] [16] [17] The potential expansion of TAVR into 
Extent of Cardiac Changes and Outcome
With the potential expansion of TAVR into lower-risk cohorts, the burden of extra cardiac comorbidities and frailty might be lessened, therefore emphasizing the importance of performing a comprehensive anatomical or structural and functional evaluation of cardiac changes before TAVR. Généreux et al 13 have shown, using data from the large PARTNER 2 trial, that the proposed staging system was among the strongest independent prognostic tools of 1-year mortality after aortic valve replacement after controlling for important indicators such as STS-PROM score, presence of frailty, coronary artery disease, renal disease, or oxygendependent chronic obstructive pulmonary disease. 13 Of importance, staging can be easily performed with the review of echocardiograms and clinical data. This study confirms the Généreux et al 13 findings: We showed that the results are reproducible and prognostically sound in a completely independent and large cohort of patients who received TAVR. Furthermore, we expanded on these findings in 2 ways. First, the study demonstrated that the association of staging with all-cause mortality persists up to 2 years of follow-up. Second, for the first time, we showed the association of staging and post-TAVR readmission rates. Specifically, patients who presented with advanced pulmonary hypertension and/or significant tricuspid regurgitation (stage 3) had higher post-TAVR readmission rates for both cardiac and noncardiac causes up to 2 years. This finding is consistent with the recent report by McCarthy et al, 19 which used data from the STS/American College of Cardiology Transcatheter Valve Therapy Registry and demonstrated that 1-year heart failure hospitalization after TAVR was independently associated with the presence of baseline severe pulmonary hypertension and severe tricuspid regurgitation. In addition, our findings build on the previous work of our group 17, 20, 21 that emphasized the importance of considering the assessment of the right-side unit in patients undergoing TAVR, not only for mortality but also for readmission purposes and potential health care costs. Whether this proposed staging classification system, bearing its simplifications and limitations, could serve as a framework for monitoring disease progression and making early referral to interventions for patients who start to demonstrate extravalvular cardiac dysfunction will require further study and a larger prospective evaluation.
Limitations
This study has limitations. First, before the TAVR era, echocardiography imaging was not necessarily performed with standard protocols, which resulted in 18 patients not having complete echocardiographic data to allow staging classification. Second, there was heterogeneity in the TAVR devices used over time, which means that some patients in the early part of the study period may have experienced firstgeneration TAVR systems but may have had better outcomes with second-or third-generation devices. Third, data on functional variable measures, such as the Kansas City Cardiomyopathy Questionnaire, 5-minute walk test, and/or objective frailty assessment, were not consistently collected. Lack of such data limited the comparison with TVT (transcatheter valve therapy)-TAVR risk scores. Although frailty is an important variable in decision making and risk stratification in patients receiving TAVR, it has been shown to not have an interaction with the proposed staging system. 13 Fourth, all patients in the cohort were treated at a medical center with a high volume of TAVR procedures performed by experienced operators; thus, the results may not be generalizable to smaller centers with a lower clinical volume of TAVR. Finally, we acknowledge that data from a single-center, retrospective study may not be sufficient to fully validate the proposed staging system. However, our homogeneous and well-phenotyped cohort of symptomatic patients with severe aortic stenosis who received TAVR, along with the demonstrated association of aortic stenosis staging with high post-TAVR cardiac and noncardiac readmissions, could add clinical value to the improvement of patient care and the development of risk stratification tools.
Conclusions
The proposed aortic stenosis staging classification system, encompassing the extent of cardiac changes, appears to have a graded association with all-cause mortality and important clinical outcomes, such as post-TAVR readmission rates for cardiac and noncardiac causes. These findings could potentially improve patient care, risk stratification systems, assessment of prognosis, and shared decision making for patients with aortic stenosis. Larger prospective studies are warranted in the future.
